PDCD1 and metastatic melanoma: Toripalimab as a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1 (PD-1) was approved for the treatment of unresectable or metastatic melanoma after the failure of previous systemic therapy in China on December 17th, 2018 [1].